ClinicalTrials.gg
Not yet recruitingNCT07719127Updated Oct 27, 2026

Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma

A Phase 1 interventional study of Disulfiram (DSF) in Brain (Nervous System) Cancers, sponsored by Case Comprehensive Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Case Comprehensive Cancer Center · Phase 1, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now Not yet recruitingNow Suspended+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Neurologic Manifestations with a site in United States — 24 open to participants now, 38 under way, 6 of them phase 3. Neurologic Manifestations · United States.

Planned enrollment
91st of 136
20 · median 34
Started
2026
with 8 others
Phase 1
20 of 185
2 open now
Primary completion
2027-12
later than 24 of 37 live
Registered
185th of 185
by date

Among the 185 studies in Neurologic Manifestations with a site in United States, this one is the 91st largest by planned enrollment of the 136 interventional ones that give a count, is one of 9 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 24 of the 37 other live ones, and was the 185th registered.

Neurologic Manifestations

427 studies on the registry are indexed under Neurologic Manifestations; 80 are open to participants now.

Browse Neurologic Manifestations studies →

Open to participants now

24 of the 185 studies in Neurologic Manifestations with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 59 Neurologic Manifestations studies recruiting now, 31 (53%) set no upper age limit and 15 (25%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Neurologic Manifestations with a site in United States, or all of them as a file.
02

Study summary

This research study is for participants with glioblastoma. It can cause a tumor immunosuppression which helps myeloid cells that can stop T-cell function. Disulfiram is a drug that has been used in treating other disorders, but this study will examine if disulfiram can help make the tumor environment less immunosuppressive and reduce brain swelling when taken before surgery.

Read the detailed description

Glioblastoma is one of the most common brain cancers that affect adults and is very hard to treat. This is due to myeloid cells, which are special immune cells in the body that prevent the body from recognizing and attacking the tumor. Because of this, immunotherapies have not worked well in treating glioblastoma.

Disulfiram may also reduce brain swelling, which may decrease or delay the need for subjects to be treated with steroids.

The purpose of this study is to find out if disulfiram can help reduce immunosuppression and help prevent edema symptoms when taken 3-14 days before planned surgery.

03

Conditions studied

  • Brain (Nervous System) Cancers

Keywords

  • brain and nervous system
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Radiographically suspected or confirmed high-grade glioma planned for surgical resection as part of standard clinical care.
  • Able to start disulfiram at least 3 days prior to planned surgery (treatment window 3-14 days pre-op).
  • In-patient status for the duration of study.
  • Performance Status (KPS) ≥70%.
  • Adequate organ function within 14 days prior to first dose:

    • ≥1.5 x 10\^9/L
    • ≥100 x 10\^9/L
    • ≥9 g/dL
    • /ALT ≤2.5 x
    • Total ≤1.5 x ULN (unless Gilbert syndrome, in which case \<5 x ULN).
  • Total bilirubin ≤1.5 x ULN (unless Gilbert syndrome, in which case \<5 x ULN).
  • Ability to understand and willingness to sign written .
  • Willingness to avoid alcohol and alcohol-containing products during treatment and for 14 days after last dose.

Exclusion criteria

Exclusion Criteria:

  • Any dexamethasone (or other systemic for cerebral edema) administered prior to enrollment/first dose (including outpatient or ED administration). This does not include inhalers or topical steroids.
  • Imaging features that are atypical for high-grade glioma that have reasonable concern for competing differential diagnoses (e.g. PCNSL, tumefactive MS, etc.)
  • Known to disulfiram or thiuram derivatives.
  • Active or severe hepatic disease (e.g. hepatitis, cirrhosis, known liver disease that may be exacerbated by disulfiram), or baseline liver tests above inclusion thresholds.
  • Current use of metronidazole or other interacting medications. See section 6.0; medication reconciliation for the list of medications/foods.
  • Pregnant or breastfeeding. Pregnant women are excluded from the trial because the safety in pregnancy has not been established. Women who are breastfeeding are excluded from the trial because it is not known if disulfiram is present in breast milk.
  • Clinically unstable neurologic status requiring immediate steroid initiation, where delaying dexamethasone for a disulfiram trial would be unsafe (investigator judgment).
  • Any condition that would limit compliance with alcohol avoidance or study procedures, or that would make participation unsafe in investigator judgment.
  • Subjects receiving any other agents.
  • Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled or unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Disulfiram

    description here

    Drug: Disulfiram (DSF)

Interventions

  • DrugDisulfiramStudies of DisulfiramDisulfiram pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    250 milligrams (mg) disulfiram will be given daily for 3-14 prior to operation. Participants can have the option to be treated at 500mg after initial evaluation.

06

What researchers measure

Primary outcomes

  1. Reduction in Complement Immunosuppressive program

    Evaluate whether disulfiram given pre-operation reduces the Complement Immunosuppressive myeloid program scores vs historical controls, which will be compared using a two-sample Wilcoxon rank-sum test (primary) and a two-sample t-test on the participant-level program scores (sensitivity). Measured using scRNA-sequence data.

    Time frame: day 0, up to 14 days

  2. Reduction in Scavenger Immunosuppressive program

    Evaluate whether disulfiram given pre-operation reduces the Scavenger Immunosuppressive myeloid program scores vs historical controls, which will be compared using a two-sample Wilcoxon rank-sum test (primary) and a two-sample t-test on the participant-level program scores (sensitivity). Measured using scRNA-sequence data.

    Time frame: day 0, up to 14 days

Secondary outcomes

  1. Proportion of participants needing dexamethasone within 48 hour window

    Change in investigator-rated edema symptom composite score from baseline to Day 2 on therapy.

    Time frame: 48 hours

  2. Safety of disulfiram

    Safety is defined as the rates of adverse events experienced by participants. Adverse event severity is graded according to the NCI Common Terminology for Adverse Events (CTCAE) Version 5.0

    Time frame: 14 days

  3. Change in Edema Symptom Composite Score (ESCS)

    Change in ESCS is analyzed using a Wilcoxon signed-rank test

    Time frame: day 0, up to 14 days

  4. Tolerability of disulfiram

    Tolerability as measured by participant toxicity rates.

    Time frame: 14 days

  5. Change in Microglial Inflammatory program scores

    Evaluate the change in microglial inflammatory program scores vs historical controls, which will be compared using a two-sample Wilcoxon rank-sum test (primary) and a two-sample t-test on the participant-level program scores (sensitivity). Measured using scRNA-sequence data.

    Time frame: day 0, up to 14 days

  6. Change in Systemic Inflammatory Program Scores

    Evaluate the change in systemic inflammatory program scores vs historical controls, which will be compared using a two-sample Wilcoxon rank-sum test (primary) and a two-sample t-test on the participant-level program scores (sensitivity). Measured using scRNA-sequence data.

    Time frame: day 0, up to 14 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie published results will be shared, as permitted by the informed consent, IRB approval, and institutional policy. This may include data dictionaries and de-identified clinical data elements needed to reproduce reported analyses, including eligibility and baseline characteristics, disulfiram exposure, dexamethasone/steroid exposure, edema-related symptom assessments, safety/adverse event data, and correlative assay-derived results from blood, tumor tissue, and CSF. Individual-level molecular, single-cell, spatial, or sequencing data will be shared only in de-identified and/or controlled-access form, as appropriate.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data supporting published results will be made available beginning after publication of the primary results and completion of institutional review for data release. Data will remain available for at least 3 years after publication, or longer if required by repository, journal, sponsor, or institutional policy.

Access criteria: Access will be provided to qualified investigators for scientifically and ethically appropriate research uses, after review and approval of a written request, execution of any required data use agreement, and confirmation that the proposed use is consistent with the informed consent, IRB approval, and institutional policies. Controlled-access data will not include direct identifiers.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartEst.
Oct 2026
Primary completionEst.
Dec 17, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Suspended→Not yet recruiting Reason for stopping removed
changed Oct 22, 2026 · changed Oct 27, 2026
Contact
Study contact now listed: added t•••@uhhospitals.org · •••7122. See the current contact
Oct 27, 2026
Show all 3 updates
  1. Oct 27, 2026
    Suspended→Not yet recruiting
    Why stopped Reason for stopping removed
    Contact Study contact now listed: added t•••@uhhospitals.org · •••7122. See the current contact
  2. Oct 22, 2026
    Not yet recruiting→Suspended
    Why stopped calendar pending
    + 2 other changes: verification date and contact details
  3. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07719127
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 17, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Tiffany Hodges, MD
Contact
tiffany.hodges@uhhospitals.org
216-286-7122
Tiffany Hodges, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disulfiram

Start the discussion